Interpretation of 2018 ESC Guidelines for Management of Cardiovascular Diseases during Pregnancy

doi:10.12114/j.issn.1007-9572.2018.00.351

Abstract

Abstract: Cardiovascular diseases during pregnancy is one of the most severe causes of maternal death.Since the European Society of Cardiology（ESC） issued the Guidelines for the Management of Cardiovascular Diseases during Pregnancy in 2011，new evidences have accumulated，particularly in diagnostic techniques，risk assessment，and the use of cardiovascular drugs.Therefore，the ESC revised the guideline and published a new one in August 2018.It provides detailed introduction of pre-pregnancy counseling，risk assessment，management，diagnosis and treatment of cardiovascular diseases during pregnancy，and drug use during pregnancy，especially risk factors.We are lack of corresponding clinical guidelines in China，but the number of pregnant patients with cardiovascular diseases is rising.In this paper，the main updated points of the guideline are interpreted to provide references for clinical diagnosis and treatment of cardiovascular diseases during pregnancy in China.

Key words: Cardiovascular diseases, Pregnancy, Disease management, Guideline

摘要： 妊娠期心血管疾病严重危害孕产妇健康，是导致孕产妇死亡的重要原因之一。自2011年欧洲心脏病学会（ESC）发布《妊娠期心血管疾病的管理指南》以来，又出现了很多新的证据，尤其是诊断技术、风险评估以及心血管药物使用方面。因此ESC修订了该指南，并于2018年8月发表，即《2018 ESC妊娠期心血管疾病管理指南》，对妊娠期心血管疾病的妊娠前咨询、风险评估、妊娠期管理及诊治、妊娠期药物使用等方面进行了详细阐述，更加强调风险评估。我国尚缺乏相应的临床指南，但合并有心血管疾病的妊娠患者越来越多，本文就该指南的主要更新要点进行解读，旨在为我国妊娠期心血管疾病临床诊疗提供参考。

关键词: 心血管疾病, 妊娠, 疾病管理, 指南

ZHANG Haofeng,ZHANG Jun. Interpretation of 2018 ESC Guidelines for Management of Cardiovascular Diseases during Pregnancy　[J]. Chinese General Practice, 2018, 21(36): 4415-4423. DOI: 10.12114/j.issn.1007-9572.2018.00.351.
张豪锋,张军. 《2018 ESC妊娠期心血管疾病管理指南》解读[J]. 中国全科医学, 2018, 21(36): 4415-4423. DOI: 10.12114/j.issn.1007-9572.2018.00.351.

References

［1］REGITZ-ZAGROSEK V，ROOS-HESSELINK J W，BAUERSACHS J，et al.2018 ESC guidelines for the management of cardiovascular diseases during pregnancy［J］.Eur Heart J，2018，39（34）：3165-3241.DOI：10.1093/eurheartj/ehy340.
［2］European Society of Gynecology（ESG），Association for European Paediatric Cardiology（AEPC），German Society for Gender Medicine（DGesGM），et al.ESC guidelines on the management of cardiovascular diseases during pregnancy［J］.Eur Heart J，2011，32（24）：3147-3197.DOI：10.1093/eurheartj/ehr218.
［3］FARR A，LENZ-GEBHART A，EINIG S，et al.Outcomes and trends of peripartum maternal admission to the intensive care unit［J］.Wien Klin Wochenschr，2017，129（17/18）：605-611.DOI：10.1007/s00508-016-1161-z.
［4］PIJUAN-DOMENECH A，GALIAN L，GOYA M，et al.Cardiac complications during pregnancy are better predicted with the modified WHO risk score［J］.Int J Cardiol，2015，195：149-154.DOI：10.1016/j.ijcard.2015.05.076.
［5］KATRITSIS D G，BORIANI G，COSIO F G，et al.European Heart Rhythm Association（EHRA） consensus document on the management of supraventricular arrhythmias，endorsed by Heart Rhythm Society（HRS），Asia-Pacific Heart Rhythm Society（APHRS），and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia（SOLAECE）［J］.Europace，2017，19（3）：465-511.DOI：10.1093/europace/euw301.
［6］GREER I A，NELSON-PIERCY C.Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thrombo embolism in pregnancy：a systematic review of safety and efficacy［J］.Blood，2005，106（2）：401-407.DOI：10.1182/blood-2005-02-0626.
［7］CANTWELL R，CLUTTON-BROCK T，COOPER G，et al.Saving mothers’ lives：reviewing maternal deaths to make motherhood safer：2006—2008.The eighth report of the confidential enquiries into maternal deaths in the United Kingdom［J］.BJOG，2011，118
（11）：1-203.DOI：10.1111/j.1471-0528.2010.02847.x.
［8］KNIGHT M，NAIR M，TUFFNELL D，et al.Saving lives，improving mothers’ care-surveillance of maternal deaths in the UK 2012—2014 and lessons learned to inform maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2009—2014［D］.Oxford：National Perinatal Epidemiology Unit，University of Oxford：2016.
［9］VAN HAGEN I M，BOERSMA E，JOHNSON M R，et al.Global cardiac risk assessment in the registry of pregnancy and cardiac disease：results of a registry from the European Society of Cardiology［J］.Eur J Heart Fail，2016，18（5）：523-533.DOI：10.1002/ejhf.501.
［10］ELKAYAM U，GOLAND S，PIEPER P G，et al.High-risk cardiac disease in pregnancy：Part Ⅰ［J］.J Am Coll Cardiol，2016，68（4）：396-410.DOI：10.1016/j.jacc.2016.05.048.
［11］ROOS-HESSELINK J W，BUDTS W，WALKER F，et al.Organisation of care for pregnancy in patients with congenital heart disease［J］.Heart，2017，103（23）：1854-1859.DOI：10.1136/heartjnl-2017-311758.
［12］VAN DER LINDE D，KONINGS E E，SLAGER M A，et al.Birth prevalence of congenital heart disease worldwide：a systematic review and meta-analysis［J］.J Am Coll Cardiol，2011，58（21）：2241-2247.DOI：10.1016/j.jacc.2011.08.025.
［13］GILL H K，SPLITT M，SHARLAND G K，et al.Patterns of recurrence of congenital heart disease：an analysis of 6，640 consecutive pregnancies evaluated by detailed fetal echocardiography［J］.J Am Coll Cardiol，2003，42（5）：923-929.
［14］Authors/Task Force Members，ELLIOTT P M，ANASTASAKIS A，et al.2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy［J］.Eur Heart J，2014，35（39）：2733-2779.DOI：10.1093/eurheartj/ehu284.
［15］CAULDWELL M，PATEL R R，STEER P J，et al.Managing subfertility in patients with heart disease：what are the choices?［J］.Am Heart J，2017，187：29-36.DOI：10.1016/j.ahj.2017.02.007.
［16］中华医学会妇产科学分会产科学组.妊娠合并心脏病的诊治专家共识（2016）［J］.中华妇产科杂志，2016，51（6）：401-409.DOI：10.3760/cma.j.issn.0529-567x.2016.06.001.
［17］BALINT O H，SIU S C，MASON J，et al.Cardiac outcomes after pregnancy in women with congenital heart disease［J］.Heart，2010，96（20）：1656-1661.DOI：10.1136/hrt.2010.202838.
［18］MANDALENAKIS Z，ROSENGREN A，SKOGLUND K，et al.Survivorship in children and young adults with congenital heart disease in Sweden［J］.JAMA Intern Med，2017，177（2）：224-230.DOI：10.1001/jamainternmed.2016.7765.
［19］SLIWA K，VAN HAGEN I M，BUDTS W，et al.Pulmonary hypertension and pregnancy outcomes：Data from the Registry of Pregnancy and Cardiac Disease（ROPAC） of the European Society of Cardiology［J］.Eur J Heart Fail，2016，18（9）：1119-1128.DOI：10.1002/ejhf.594.
［20］徐晓辉，张军，王慧，等.妊娠合并严重特发性肺动脉高压十例临床分析［J］.中华妇产科杂志，2014，49（6）：419-423.DOI：10.3760/cma.j.issn.0529-567x.2014.06.005.
XU X H，ZHANG J，WANG H，et al.Severe idiopathic pulmonary arterial hypertension in pregnancy：a review of 10 cases［J］.Chinese Journal of Obstetrics and Gynecology，2014，49（6）：419-423.DOI：10.3760/cma.j.issn.0529-567x.2014.06.005.
［21］包照亮，张军，杨冬，等.妊娠合并肺动脉高压死亡患者的临床高危因素特征分析［J］.中华妇产科杂志，2014，49（7）：495-500.DOI：10.3760/cma.j.issn.0529-567x.2014.07.005.
BAO Z L，ZHANG J，YANG D，et al.Analysis of high risk factors for patient death and its clinical characteristics on pregnancy associated with pulmonary arterial hypertension［J］.Chinese Journal of Obstetrics and Gynecology，2014，49（7）：495-500.DOI：10.3760/cma.j.issn.0529-567x.2014.07.005.
［22］ZHAO H，ZHANG H，XU X，et al.Risk factors for perinatal cardiac complications in pregnancy with pulmonary hypertension［J］.Pregnancy Hypertension，2018，12：207-213.DOI：10.1016/j.preghy.2017.09.001.
［23］SMITH K，GROS B.Pregnancy-related acute aortic dissection in Marfan syndrome：a review of the literature［J］.Congenit Heart Dis，2017，12（3）：251-260.DOI：10.1111/chd.12465.
［24］PYERITZ R E.Maternal and fetal complications of pregnancy in the Marfan syndrome［J］.Am J Med，1981，71（5）：784-790.
［25］HAMEED A，KARAALP I S，TUMMALA P P，et al.The effect of valvular heart disease on maternal and fetal outcome of pregnancy［J］.J Am Coll Cardiol，2001，37（3）：893-899.
［26］VAN HAGEN I M，THORNE S A，TAHA N，et al.Pregnancy outcomes in women with rheumatic mitral valve disease：Results from the Registry of Pregnancy and Cardiac Disease［J］.Circulation，2018，137（8）：806-816.DOI：10.1161/CIRCULATIONAHA.117.032561.
［27］SILVERSIDES C K，COLMAN J M，SERMER M，et al.Cardiac risk in pregnant women with rheumatic mitral stenosis［J］.Am J Cardiol，2003，91（11）：1382-1385.
［28］ELKAYAM U，JALNAPURKAR S，BARAKKAT M N，et al.
Pregnancy-associated acute myocardial infarction：a review of contemporary experience in 150 cases between 2006 and 2011［J］.Circulation，2014，129（16）：1695-1702.DOI：10.1161/CIRCULATIONAHA.113.002054.
［29］HAGHIKIA A，PODEWSKI E，LIBHABER E，et al.Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy［J］.Basic Res Cardiol，2013，108（4）：366-366.DOI：10.1007/s00395-013-0366-9.
［30］LIBHABER E，SLIWA K，BACHELIER K，et al.Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy［J］.Int J Cardiol，2015，190：376-382.DOI：10.1016/j.ijcard.2015.04.081.
［31］BITEKER M，ILHAN E，BITEKER G，et al.Delayed recovery in peripartum cardiomyopathy：an indication for long-term follow-up and sustained therapy［J］.Eur J Heart Fail，2012，14（8）：895-901.DOI：10.1093/eurjhf/hfs070.
［32］SPIRITO P，AUTORE C.Management of hypertrophic cardiomyopathy［J］.BMJ，2006，332（7552）：1251-1255.DOI：10.1136/bmj.332.7552.1251.
［33］METRA M.September 2016 at a glance：pregnancy，hypertrophic cardiomyopathy，epidemiology，medical treatment［J］.Eur J Heart Fail，2016，18（9）：1091-1092.DOI：10.1002/ejhf.627.
［34］SCHINKEL A F.Pregnancy in women with hypertrophic cardiomyopathy［J］.Cardiol Rev，2014，22（5）：217-222.DOI：10.1097/CRD.0000000000000010.
［35］VAN TINTELEN J P，PIEPER P G，VAN SPAENDONCK-ZWARTS K Y，et al.Pregnancy，cardiomyopathies，and genetics［J］.Cardiovasc Res，2014，101（4）：571-578.DOI：10.1093/cvr/cvu014.
［36］AUTORE C，CONTE M R，PICCININNO M，et al.Risk associated with pregnancy in hypertrophic cardiomyopathy［J］.J Am Coll Cardiol，2002，40（10）：1864-1869.
［37］VAIDYA V R，ARORA S，PATEL N，et al.Burden of arrhythmia in pregnancy［J］.Circulation，2017，135（6）：619-621.DOI：10.1161/CIRCULATIONAHA.116.026681.
［38］VILLAR J，CARROLI G，WOJDYLA D，et al.Preeclampsia，gestational hypertension and intrauterine growth restriction，related or independent conditions?［J］.Am J Obstet Gynecol，2006，194（4）：921-931.DOI：10.1016/j.ajog.2005.10.813.

[1]	YU Xinyan, ZHAO Jun, ZHAO Xiaoye, JIANG Qingru, CHEN Yatian, WANG Yan, ZHANG Haicheng. Application of Mobile Smart Healthcare in the Prevention and Control of Cardiovascular Diseases in Elderly Patients with Chronic Diseases in Primary Care [J]. Chinese General Practice, 2023, 26(33): 4167-4172.
[2]	WANG Minghuan, LI Yuhong, YU Min, WANG Yougang, YU Qiaozhi, YANG Fangfang, YUAN Dehui, ZHANG Liu. Effect of Allostatic Load on Adverse Pregnancy Outcomes of Women in Late Pregnancy [J]. Chinese General Practice, 2023, 26(32): 4064-4069.
[3]	YUAN Dehui, LI Yuhong, XIONG Min, YU Min, MA Ruiliang, YANG Fangfang, YU Qiaozhi, WANG Minghuan. Status and Influencing Factors of Allostatic Load in Pregnant Women at Different Trimesters [J]. Chinese General Practice, 2023, 26(32): 4057-4063.
[4]	HUANG Taishuai, CHI Yan, HE Ping, HUANG Guolan, ZUO Yanli. Cost-effectiveness Analysis of GnRH Antagonist Protocol and Short-acting GnRH Agonist Long Protocol in Fresh Embryo Transfer Based on Propensity Score Matching [J]. Chinese General Practice, 2023, 26(30): 3809-3814.
[5]	PAN Yaojia, WANG Weiqiang, YI Weizhuo, GAO Bing, FU Fanglin, HAN Zheng, SUN Meng, DONG Yaqin, GU Huaicong. Relationship between Triglyceride-glucose Index and Risk of Cardiovascular Diseases in Middle-aged Obese Residents of Different Genders [J]. Chinese General Practice, 2023, 26(29): 3628-3635.
[6]	YUAN Xianxian, WANG Jia, ZHANG Kexin, YANG Ruihua, ZHENG Wei, LI Guanghui. Association between Blood Lipid Levels and Macrosomia in Pregnant Women with Different Pre-pregnancy Body Mass Index [J]. Chinese General Practice, 2023, 26(24): 2973-2979.
[7]	ZHANG Li, ZHENG Wei, WANG Jia, YUAN Xianxian, HAN Weiling, HUANG Junhua, TIAN Zhihong, LI Guanghui. Comparison of Gestational Weight Gain and Pregnancy Outcomes in Chinese Women with Singleton Pregnancy Using Standard of Recommendation for Weight Gain during Pregnancy Period and Guidelines by the Institute of Medicine [J]. Chinese General Practice, 2023, 26(24): 2959-2967.
[8]	CHE Guoyu, MA Aqin, YANG Lan, LI Jing, WANG Ling. Influence of Group Cognitive Behavioral Therapy on Pregnancy Outcomes among Pregnant Women with Gestational Diabetes Mellitus: a Propensity Score Matching Study [J]. Chinese General Practice, 2023, 26(24): 2968-2972.
[9]	YANG Hui. Cooperated and Shared Care: Reflections on Treatment-prevention Integration [J]. Chinese General Practice, 2023, 26(22): 2711-2714.
[10]	DENG Hongyu, WU Miaomiao, YANG Zheng, HE Yang, ZHU Linlin, ZHAO Qian, DAI Hua, WU Jia, LIAO Xiaoyang, ZHANG Yonggang. Construction of an Innovative Model of Chronic Disease Management in Compact County Medical Alliance with Treatment-prevention Integration [J]. Chinese General Practice, 2023, 26(22): 2720-2725.
[11]	WANG Minghuan, LI Yuhong, YUAN Dehui, YU Min, HAN Baoliang, YU Qiaozhi, YANG Fangfang, ZHANG Qin. Correlation between Allostatic Load Level and Depression among Women in Early Pregnancy [J]. Chinese General Practice, 2023, 26(21): 2609-2613.
[12]	WANG Jingyu, HONG Shenda, HAN Fang, LIU Guoli. A Review of Recent Advances in Screening for Obstructive Sleep Apnea during Pregnancy [J]. Chinese General Practice, 2023, 26(20): 2555-2558,2566.
[13]	TIAN Meixiang, ZHANG Zhengyi. Standard Management of Hypertension During the Preparation for Pregnancy [J]. Chinese General Practice, 2023, 26(18): 2190-2194.
[14]	SUN Jingjing, ZHANG Yan, KUANG Wenbo, LUO Yimeng, HUANG Pengqun, MAIREYAMUGULI· Aihemaiti, JIN Mengyuan, GAO Zeyu, DU Hanlin, DAI Xiaojie. Willingness to Refer Patients with Common Illnesses to Lower Level Institutions and Associated Factors in County Hospital Physicians [J]. Chinese General Practice, 2023, 26(10): 1205-1211.
[15]	LIU Taotao, LI Tianrong, WANG Xue, CHEN Jiameng, SHUAI Zhiqin, LI Lisheng, XU Shangfu. Nanoparticle- and Exosome-based Targeted Drug Delivery Systems Used in the Diagnosis and Treatment of Atherosclerosis: Opportunities and Challenges [J]. Chinese General Practice, 2023, 26(08): 903-910.